NasdaqGM - Nasdaq Real Time Price USD
ArriVent BioPharma, Inc. (AVBP)
20.64
+1.28
+(6.64%)
As of 2:39:05 PM EDT. Market Open.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
Total Revenue
0
0
0
0
Operating Expense
140,406
94,308
74,590
36,906
Operating Income
-140,406
-94,308
-74,590
-36,906
Net Non Operating Interest Income Expense
12,948
13,820
5,257
0
Pretax Income
-127,458
-80,488
-69,333
-36,906
Net Income Common Stockholders
-127,458
-80,488
-69,333
-36,906
Diluted NI Available to Com Stockholders
-127,458
-80,488
-69,333
-36,906
Basic EPS
-3.76
--
-2.17
-1.15
Diluted EPS
-3.76
--
-2.17
-1.15
Basic Average Shares
33,682.41
--
31,956.66
31,956.66
Diluted Average Shares
33,682.41
--
31,956.66
31,956.66
Total Operating Income as Reported
-140,406
-94,308
-74,590
-36,906
Total Expenses
140,406
94,308
74,590
36,906
Net Income from Continuing & Discontinued Operation
-127,458
-80,488
-69,333
-36,906
Normalized Income
-127,458
-80,488
-69,333
-36,906
Interest Income
12,948
13,820
5,257
0
Net Interest Income
12,948
13,820
5,257
0
EBIT
-140,406
-94,308
-74,590
-36,906
EBITDA
-140,406
-94,308
-74,590
-36,906
Net Income from Continuing Operation Net Minority Interest
-127,458
-80,488
-69,333
-36,906
Normalized EBITDA
-140,406
-94,308
-74,590
-36,906
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
12/31/2022 - 1/26/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MBX MBX Biosciences, Inc.
12.03
-0.99%
ORYZF Oryzon Genomics S.A.
3.0300
0.00%
DB0.F Q32 Bio Inc.
1.4900
-1.97%
2160.T GNI Group Ltd.
2,589.00
+0.12%
ORN.MU Oryzon Genomics SA
2.6200
0.00%
PHM.VI Pharma Mar, S.A.
83.05
+4.20%
0RC6.IL Pharma Mar, S.A.
82.95
+3.24%
CTNM Contineum Therapeutics, Inc.
3.9201
-10.30%
ORN.F Oryzon Genomics S.A.
2.5650
-1.91%
ARTV Artiva Biotherapeutics, Inc.
2.1250
+5.21%